Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Abuckatatime who wrote (2458)	2/6/1999 12:08:00 AM
From: Greg Rich	Respond to of 4676

Agreed! Greg

To: Abuckatatime who wrote (2458)	2/6/1999 3:43:00 PM
From: John	Read Replies (1) \| Respond to of 4676

I agree. My problem is that it seems that someone knew about the offering before the S3 was filed and has been shorting the stock. Why doesn't the SEC nail these people--this happens every day, and it's not hard to look and see who the offenders are.

To: Abuckatatime who wrote (2458)	2/7/1999 12:23:00 PM
From: LLCF	Read Replies (1) \| Respond to of 4676

< May the $50 mil from this offering help bring 2302, 3521, 5132, and the others successfully to market. That's the payoff. A revenue stream from anti-virals, anti-inflammatories, anti-Ca's, drug discovery and target validation collaborations, etc., that proves that the $50 mil worth of dilution was money well spent.> While often secondary offerings don't seem to make sense because of the dilution, I think in this business these guys figure "better safe than sorry" as far as their cash position goes. Some anecdotal evidence to ponder: ENZN did a secondary @ around $5 last summer, and is currently trading $14. I'm sure there is anecdotal evidence showing the opposite as well, BUT IMO at least we know there are people out there doing TONS of due diligence that have come to the conclusion this company is a good investment. DAK